Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1–4 inhibitor in patients with advanced solid tumors

  1. Bahleda, R.
  2. Meric-Bernstam, F.
  3. Goyal, L.
  4. Tran, B.
  5. He, Y.
  6. Yamamiya, I.
  7. Benhadji, K.A.
  8. Matos, I.
  9. Arkenau, H.-T.
Journal:
Annals of Oncology

ISSN: 1569-8041,  0923-7534

Year of publication: 2020

Volume: 31

Issue: 10

Pages: 1405-1412

Type: Article

DOI: 10.1016/J.ANNONC.2020.06.018 GOOGLE SCHOLAR lock_openOpen access editor
Data source: Scopus